Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famotidine and N-Acetyl Cysteine in Outpatient SARS-CoV-2 Infection
NCT04545008Phase 1Terminated
- Sponsor
- Prisma Health
- Start
- Oct 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of famotidine and acetylcysteine in coronavirus disease 2019 (COVID-19) (12 arms), sponsored by Prisma Health. Primary endpoint: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v5.0 at 30 days. Started Oct 2020; status: terminated.
02
Drugs
famotidineacetylcysteine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04545008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04545008.